Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patients

Launched by S.LAB (SOLOWAYS) · Mar 10, 2025

Keywords

ClinConnect Summary

This pilot study, titled "Pilot Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Natural Genome Reconstruction Technology in Hematopoietic Stem Cells in Adult Patients," investigates the use of hDNAgr technology-which involves the administration of fragmented therapeutic double-stranded DNA-to achieve natural genomic reconstruction in hematopoietic stem cells. The hypothesis is that this intervention will lead to a safe and controlled correction of damaged genomic regions and telomere elongation, thereby improving hematopoietic parameters (evidenced by restor...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • . Men and women aged 45 to 65 years inclusive (optimal age range for a pilot study of the effect on aging processes).
• • Confirmed absence of serious chronic diseases in the decompensation stage (based on the results of a standard clinical and laboratory examination).
• • No history of malignant neoplasms over the past 5 years. Written informed consent to participate in the study. Willingness to comply with the study protocol, including attending all scheduled visits and undergoing the required diagnostic procedures.
• Exclusion Criteria:
• • Pregnancy, lactation, or planning a pregnancy during the study.
• • The presence of immunodeficiency states (HIV infection, severe autoimmune diseases, etc.) in the acute stage.
• • Decompensated cardiovascular, hepatic, renal pathologies (a conclusion from a therapist or a specialized specialist is required).
• • Take immunosuppressants, corticosteroids or chemotherapeutic drugs within 3 months before screening.
• • Alcohol or drug addiction, confirmed by medical documents or identified during screening.
• • Participation in other clinical trials 30 days before inclusion or planned participation during this study.
• • Observation plan, duration of Follow-Up and number of visits